(Press-News.org) CHICAGO, JUNE 1, 2013 — The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology (ASCO).
The findings are potentially practice-changing for a historically "untreatable disease." Though uveal melanoma is rare — there are only 2,500 cases diagnosed in the United States each year — about half of patients will develop metastatic disease, and survival for patients with advanced disease has held steady at nine months to a year for decades.
Researchers found that progression-free survival (PFS) in patients receiving selumetinib was nearly 16 weeks and 50 percent of these patients experienced tumor shrinkage, with 15 percent achieving major shrinkage. Patients receiving temozolomide, the current standard chemotherapy, had seven weeks of PFS and no tumor shrinkage. Selumetinib also lengthened overall survival to 10.8 months versus 9.4 months with temozolomide, and side effects were manageable.
"This is the first study to show that a systemic therapy provides significant clinical benefit in a randomized fashion to advanced uveal melanoma patients, who have very limited treatment options," said Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering and lead author on the study. "This clinical benefit has never been demonstrated with other conventional or investigational agents, which is all we have been able to offer patients for decades."
Dr. Carvajal and his team decided to test selumetinib because it blocks the MEK protein, a key component of the tumor-driving MAPK pathway. This pathway is activated by mutations in the Gnaq and Gna11 genes, which occur in more than 85 percent of uveal melanoma patients; 84 percent of patients in this trial had one of the mutations.
Uveal melanoma does not respond to the drugs given to patients with melanoma on the skin; and, in fact, there is no drug approved specifically for treatment of the disease. Patients with uveal melanoma receive surgery to remove the tumor — and in some advanced cases, the entire eye — as well as radiation therapy or chemotherapy.
In the trial, researchers randomized 98 patients with metastatic uveal melanoma and administered selumetinib to 47, of which 81 percent had a Gnaq or Gna11 mutation. Of the 49 patients who received temozolomide, 86 percent had a mutation. Two patients were not treated. Despite the study's cross-over design — meaning patients whose tumors progressed on temozolomide could begin taking selumetinib — there was a trend towards improved survival with selumetinib. Selumetinib was generally tolerable, with most side effects manageable with conservative management or dose modification.
Dr. Carvajal is currently planning a confirmatory multi-center, randomized trial that will enroll approximately 100 patients and be led by Memorial Sloan-Kettering. "If we can confirm selumetinib's effectiveness in treating advanced uveal melanoma in this follow-up trial, it will become the standard therapy for this disease, forming a foundation for new drug combinations that could maximize selumetinib's MEK-inhibitor effect," he said. "It could offer a whole new way to treat this historically untreatable disease."
###
The current research was supported by a Conquer Cancer Foundation of ASCO Career Development Award, the National Institutes of Health, Cycle for Survival, and the Fund for Ophthalmic Knowledge.
Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose, and treat cancer. Memorial Sloan-Kettering specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide. For more information, go to http://www.mskcc.org.
New drug improves progression-free survival, shrinks tumors in rare cancer for first time
2013-06-01
ELSE PRESS RELEASES FROM THIS DATE:
No increased risk of infection for long-term sex partners of people with HPV-related oral cancers
2013-06-01
Spouses and long-term partners of patients with mouth and throat cancers related to infection with the human papilloma virus (HPV) appear to have no increased prevalence of oral HPV infections, according to results of a multicenter, pilot study led by Johns Hopkins investigators. The study's results suggest that long-term couples need not change their sexual practices, say the scientists.
"While we can't guarantee that the partners of patients will not develop oral HPV infections or cancers, we can reassure them that our study found they had no increased prevalence of ...
Acidifying oceans could spell trouble for squid
2013-06-01
Acidifying oceans could dramatically impact the world's squid species, according to a new study led by Woods Hole Oceanographic Institution (WHOI) researchers and soon to be published in the journal PLOS ONE. Because squid are both ecologically and commercially important, that impact may have far-reaching effects on the ocean environment and coastal economies, the researchers report.
"Squid are at the center of the ocean ecosystem—nearly all animals are eating or eaten by squid," says WHOI biologist T. Aran Mooney, a co-author of the study. "So if anything happens to ...
Procedures saving limbs of more peripheral arterial disease patients, Mayo Clinic finds
2013-06-01
SAN FRANCISCO -- Peripheral arterial disease is a common circulation problem in which reduced blood flow can lead to complications that jeopardize the limbs, possibly even requiring amputation. Procedures known as revascularization have reduced the need for amputations 40 percent over two decades, Mayo Clinic research shows. The findings were among several studies presented at the Society for Vascular Surgery annual meeting in San Francisco.
In the amputation study, Mayo researchers analyzed patients in the Rochester Epidemiology Project, a National Institutes of ...
Exposure to general anaesthesia could increase the risk of dementia in elderly by 35 percent
2013-06-01
Exposure to general anaesthesia increases the risk of dementia in the elderly by 35%, says new research presented at Euroanaesthesia, the annual congress of the European Society of Anaesthesiology (ESA). The research is by Dr Francois Sztark, INSERM and University of Bordeaux, France, and colleagues.
Postoperative cognitive dysfunction, or POCD, could be associated with dementia several years later. POCD is a common complication in elderly patients after major surgery. It has been proposed that there is an association between POCD and the development of dementia due ...
Catastrophic climatic events leave corals facing a decade-long fight for recovery
2013-06-01
Marine conservationists from Plymouth University, and the Universidad Federal da Bahia in Brazil, have spent more than 17 years analysing the diversity and density of coral colonies off the coast of South America.
That coincided with the catastrophic El Niño event of 1997-98, creating an opportunity for the first detailed assessment of the long-term impact a major environmental incident of this nature can have on coral assemblages.
Professor Martin Attrill, Director of Plymouth University's Marine Institute, said: "Coral reefs are perhaps the most diverse marine ecosystem ...
Oncogene mutation hijacks splicing process to promote growth and survival
2013-06-01
An international team of researchers – led by principal investigator Paul S. Mischel, MD, a member of the Ludwig Institute for Cancer Research and professor in the Department of Pathology at the University of California, San Diego School of Medicine – has found that a singular gene mutation helps brain cancer cells to not just survive, but grow tumors rapidly by altering the splicing of genes that control cellular metabolism.
The findings are published online in the journal Cell Metabolism.
Mischel, who heads the Ludwig Institute's molecular pathology laboratory based ...
Investigators link poultry contamination on farm and at processing plant
2013-06-01
Researchers at the University of Georgia, Athens, have identified a strong link between the prevalence and load of certain food-borne pathogens on poultry farms, and later downstream at the processing plant. They report their findings in a manuscript published ahead of print in the journal Applied and Environmental Microbiology.
"This study suggests that reducing foodborne pathogen loads on broiler chicken farms would help to reduce pathogen loads at processing, and may ultimately help to reduce the risk of foodborne illness," says Roy Berghaus, an author on the study. ...
Microbial changes regulate function of entire ecosystems
2013-06-01
A major question in ecology has centered on the role of microbes in regulating ecosystem function. Now, in research published ahead of print in the journal Applied and Environmental Microbiology, Brajesh Singh of the University of Western Sydney, Australia, and collaborators show how changes in the populations of methanotrophic bacteria can have consequences for methane mitigation at ecosystem levels.
"Ecological theories developed for macro-ecology can explain the microbial regulation of the methane cycle," says Singh.
In the study, as grasslands, bogs, and moors ...
Surges in latent infections: Mathematical analysis of viral blips
2013-06-01
Philadelphia, PA—Recurrent infection is a common feature of persistent viral diseases. It includes episodes of high viral production interspersed by periods of relative quiescence. These quiescent or silent stages are hard to study with experimental models. Mathematical analysis can help fill in the gaps.
In a paper titled Conditions for Transient Viremia in Deterministic in-Host Models: Viral Blips Need No Exogenous Trigger, published last month in the SIAM Journal on Applied Mathematics, authors Wenjing Zhang, Lindi M. Wahl, and Pei Yu present a model to study persistent ...
Mathematical models to better combat HIV
2013-06-01
Philadelphia, PA—The first few hours to days following exposure to human immunodeficiency virus (HIV) can be of critical importance in determining if infection occurs in a patient. But the low numbers of viruses and infected cells at this stage makes it very difficult to study these events in humans or animal models.
Theoretical mathematical models can help analyze viral dynamics in this early phase, and hence offer insights into therapeutic and prevention strategies, as evidenced by a paper published last month in the SIAM Journal on Applied Mathematics.
In a paper ...